Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STZ-5FU followed by everolimus versus the reverse sequence in advanced pancreatic neuroendocrine tumors
2013-000726-66Phase 3Completed
- Sponsor
- Spanish Group of Neuroendocrine Tumors
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of everolimus, streptozocin and fluorouracil in islet cell tumor (2 arms), sponsored by Spanish Group of Neuroendocrine Tumors. Primary endpoint: Rate of second progression-free survival at 140 +/- 8 weeks. Started Apr 2014; status: completed.
02
Drugs
everolimusstreptozocinfluorouracil
03
Conditions
islet cell tumor
Beyond the preview
Go deeper on 2013-000726-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000726-66.